Cellphire Awarded Subaward for DARPA Biostasis Program

February 27, 2019 -- Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that the Defense Advanced Research and Development Authority (DARPA) has awarded the company a seven-figure contract in conjunction with the University of North Carolina at Chapel Hill for Research Aimed to Extend the Golden Hour for Life Saving Post Traumatic Treatment under the DARPA Biostasis Program.

The research, led by Dr. Thomas Boothby of the UNC team, focuses on leveraging proteins found in tardigrades (“water bears”) that are intrinsically disordered and adopt different conformations under environmental duress. The intrinsically disordered proteins (IDPs) enable the organisms to adopt a state of suspended animation prior to resuscitation or removal of the stress.

The UNC team is responsible for the cloning, expression, and characterization of the IDPs, while Cellphire will leverage its core blood platelet stabilization expertise to load the IDPs into blood cells and to assess the cellular and plasma protein function of the loaded blood cells.

“We are pleased to be collaborating with UNC. The DARPA award allows us to continue to develop revolutionary lyophilized cell preservation technology essential for the management of trauma-associated death and co-morbidities,” said Stephen Willard, CEO of Cellphire. “Our goals reflect our desire to maximize the chances that our servicemen and women will survive a traumatic event.”

# # # 

About Cellphire, Inc. 

Cellphire, Inc., based in Rockville, Maryland, is the only U.S. company developing freeze-dried platelet products. Cellphire is focused on applying its cellular stabilization technology to all cell types to provide lifesaving products where none are routinely available. Platelets are critical to the body’s vascular system and responsible for the body’s ability to stop bleeding. Unlike other blood products that can be frozen and stockpiled for use when needed, platelet products currently used can only be stored for 5-7 days. Cellphire’s lead product, Thrombosomes®, a human platelet derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a product that can be stored for years, then reconstituted with sterilized water. Cellphire’s platform technology has potential applications across a wide range of cell types and medical applications from trauma to wound care, imaging, targeted drug delivery and regenerative medicine. This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C. For more information, please view www.cellphire.com.

Cautionary Note Regarding Forward-Looking Statements  

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether because of new information, future events or otherwise.


Thomas Dann
(240) 268-2489

Source:  Cellphire, Inc.